Taha Mohamad R, Nguyen Harrison P, Tyring Stephen K
College of Medicine, Texas A&M University Health Science Center, Bryan, Texas.
Center for Clinical Studies, Webster, Texas.
Am J Med Open. 2025 Jul 18;14:100112. doi: 10.1016/j.ajmo.2025.100112. eCollection 2025 Dec.
Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis that results in progressive, painful ulcers most commonly affecting the lower extremities. Although immunosuppressants are frequently used for therapy, there is no standard treatment approach, and recurrences are common. The pathogenesis of PG is believed to involve dysregulation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, supporting the potential use of JAK/STAT inhibitors as a treatment option. This case series describes the successful use of upadacitinib, a selective JAK inhibitor, in the management of PG.
坏疽性脓皮病（PG）是一种罕见的嗜中性皮肤病，可导致进行性疼痛性溃疡，最常累及下肢。尽管免疫抑制剂经常用于治疗，但目前尚无标准的治疗方法，且复发很常见。PG的发病机制被认为涉及Janus激酶（JAK）/信号转导子和转录激活子（STAT）通路的失调，这支持了将JAK/STAT抑制剂作为一种治疗选择的可能性。本病例系列描述了选择性JAK抑制剂乌帕替尼在PG治疗中的成功应用。
